UPCC 09223: A Phase 2 Clinical Trial Investigating Oncolytic Immunotherapy in Combination with Atezolizumab and bevacizumab for the Treatment of Patients with Advanced Microsatellite Stable and Mismatch Repair Proficient Colorectal Carcinoma
Enrolling By Invitation
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
Please refer to Section 3.1 of the full protocol (Objectives and Endpoints) Please refer to Section 3.1 of the full protocol (Objectives and Endpoints) Please refer to Section 3.1 of the full protocol (Objectives and Endpoints)
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
01 Aug 2024.
Study ID: 854064
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
